Mae B. Hultin

651 total citations
19 papers, 513 citations indexed

About

Mae B. Hultin is a scholar working on Hematology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Mae B. Hultin has authored 19 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 4 papers in Surgery and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Mae B. Hultin's work include Blood Coagulation and Thrombosis Mechanisms (12 papers), Platelet Disorders and Treatments (10 papers) and Hemophilia Treatment and Research (7 papers). Mae B. Hultin is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (12 papers), Platelet Disorders and Treatments (10 papers) and Hemophilia Treatment and Research (7 papers). Mae B. Hultin collaborates with scholars based in United States and Norway. Mae B. Hultin's co-authors include Barry S. Coller, Raymond P. Warrell, William E. Lawson, Lisa Mills, Robin H. Miller, Silvia Spitzer, Vikas Bhushan, Jolyon Jesty, Ulrich Abildgaard and J. W. Mckay and has published in prestigious journals such as Journal of the American College of Cardiology, The American Journal of Medicine and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

Mae B. Hultin

19 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mae B. Hultin United States 12 392 125 98 85 80 19 513
BL Kass United States 8 565 1.4× 151 1.2× 109 1.1× 161 1.9× 132 1.6× 10 685
Irmela Sulzer Switzerland 14 350 0.9× 65 0.5× 96 1.0× 170 2.0× 127 1.6× 24 590
Wataru Tatewaki Japan 14 369 0.9× 125 1.0× 51 0.5× 108 1.3× 90 1.1× 41 543
M Samama France 9 253 0.6× 88 0.7× 126 1.3× 61 0.7× 129 1.6× 51 430
S Barzegar United States 11 507 1.3× 118 0.9× 222 2.3× 132 1.6× 187 2.3× 15 781
Michiaki Ohiwa Japan 11 330 0.8× 80 0.6× 77 0.8× 96 1.1× 128 1.6× 11 527
Peggy Nakagawa United States 7 408 1.0× 83 0.7× 107 1.1× 69 0.8× 82 1.0× 10 590
M.P.M. De Maat Netherlands 11 202 0.5× 110 0.9× 96 1.0× 32 0.4× 72 0.9× 16 430
Hiroyuki Uchiyama Japan 6 259 0.7× 79 0.6× 128 1.3× 43 0.5× 168 2.1× 8 475
S. C. Tso China 13 192 0.5× 79 0.6× 39 0.4× 162 1.9× 56 0.7× 24 473

Countries citing papers authored by Mae B. Hultin

Since Specialization
Citations

This map shows the geographic impact of Mae B. Hultin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mae B. Hultin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mae B. Hultin more than expected).

Fields of papers citing papers by Mae B. Hultin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mae B. Hultin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mae B. Hultin. The network helps show where Mae B. Hultin may publish in the future.

Co-authorship network of co-authors of Mae B. Hultin

This figure shows the co-authorship network connecting the top 25 collaborators of Mae B. Hultin. A scholar is included among the top collaborators of Mae B. Hultin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mae B. Hultin. Mae B. Hultin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Nichols, William L., Margaret E. Rick, Thomas L. Ortel, et al.. (2009). Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of the 2008 NHLBI/NIH guidelines. American Journal of Hematology. 84(6). 366–370. 67 indexed citations
2.
Rubenstein, David A., et al.. (2006). Platelet factor V supports hemostasis in a patient with an acquired factor V inhibitor, as shown by prothrombinase and tenase assays. Blood Coagulation & Fibrinolysis. 17(7). 593–597. 19 indexed citations
3.
Dervan, John, et al.. (1998). Lipoprotein(a) Level Does Not Predict Restenosis After Percutaneous Transluminal Coronary Angioplasty. Arteriosclerosis Thrombosis and Vascular Biology. 18(8). 1281–1286. 19 indexed citations
4.
Mills, Lisa, et al.. (1997). A Prothrombin Gene Mutation Is Significantly Associated With Venous Thrombosis. Arteriosclerosis Thrombosis and Vascular Biology. 17(11). 2875–2879. 63 indexed citations
5.
Bhushan, Vikas, et al.. (1996). Postprandial Elevation of Activated Factor VII in Young Adults. Arteriosclerosis Thrombosis and Vascular Biology. 16(11). 1327–1332. 43 indexed citations
6.
Hultin, Mae B., et al.. (1992). Dibucaine elicits platelet procoagulant activity in factor VIII and factor X activation by a mechanism involving a sulfhydryl-dependent enzyme. Thrombosis Research. 68(4-5). 399–407. 1 indexed citations
7.
Hultin, Mae B.. (1991). Acquired inhibitors in malignant and nonmalignant disease states. The American Journal of Medicine. 91(5). S9–S13. 45 indexed citations
8.
D'Acosta, N. & Mae B. Hultin. (1991). Effective therapy of human immunodeficiency virus‐associated anemia with recombinant human erythropoietin despite high endogenous erythropoietin. American Journal of Hematology. 36(1). 71–72. 5 indexed citations
9.
Hultin, Mae B. & Ira I. Sussman. (1990). Postoperative thrombocytopenia in type IIB von Willebrand disease. American Journal of Hematology. 33(1). 64–68. 18 indexed citations
10.
Hultin, Mae B., et al.. (1989). The use of polyelectrolyte-fractionated porcine factor VIII in the treatment of a spontaneously acquired inhibitor to factor VIII. Thrombosis Research. 55(1). 51–56. 12 indexed citations
11.
Miller, Robin H., et al.. (1989). Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. Journal of the American College of Cardiology. 14(4). 941–946. 64 indexed citations
12.
Hultin, Mae B., Raymond J. Dattwyler, & Richard A. Lipton. (1989). Controlled prospective study of factor IX concentrate therapy and immunodeficiency. American Journal of Hematology. 31(1). 71–72. 3 indexed citations
13.
Hultin, Mae B., J. W. Mckay, & Ulrich Abildgaard. (1988). Antithrombin Oslo: Type Ib Classification of the First Reported Antithrombin-Deficient Family, with a Review of Hereditary Antithrombin Variants. Thrombosis and Haemostasis. 59(3). 468–473. 26 indexed citations
14.
Hultin, Mae B. & Ulrich Abildgaard. (1987). Antithrombin antigen of high molecular weight associated with neoantigen in hemophilic plasma after factor IX concentrate therapy. Thrombosis Research. 45(2). 175–182. 1 indexed citations
15.
Hultin, Mae B., et al.. (1986). Factor IX concentrate therapy and thrombosis: Relation to changes in plasma antithrombin III. Thrombosis Research. 43(2). 143–151. 10 indexed citations
16.
Miller, Nancy S., et al.. (1986). Hereditary antithrombin III deficiency: Case report and review of recent therapeutic advances. American Journal of Hematology. 21(2). 215–221. 6 indexed citations
17.
18.
Jesty, Jolyon, et al.. (1981). Effect of oral contraceptives on antithrombin III. Thrombosis Research. 24(1-2). 13–20. 15 indexed citations
19.
Warrell, Raymond P., Mae B. Hultin, & Barry S. Coller. (1979). Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. The American Journal of Medicine. 66(2). 226–228. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by BL Kass Breakdown of academic impact, for papers by Irmela Sulzer Breakdown of academic impact, for papers by Wataru Tatewaki Breakdown of academic impact, for papers by M Samama Breakdown of academic impact, for papers by S Barzegar Breakdown of academic impact, for papers by Michiaki Ohiwa Breakdown of academic impact, for papers by Peggy Nakagawa Breakdown of academic impact, for papers by M.P.M. De Maat Breakdown of academic impact, for papers by Hiroyuki Uchiyama Breakdown of academic impact, for papers by S. C. Tso
Rankless by CCL
2026